Literature DB >> 15256827

Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness.

Christian R Baumann1, Yves Dauvilliers, Emmanuel Mignot, Claudio L Bassetti.   

Abstract

Excessive daytime sleepiness, hallucinations and REM sleep behavior disorder are symptoms reported in both dementia with Lewy bodies (DLB) and narcolepsy. Considering the demonstration of low hypocretin-1/orexin A levels in the cerebrospinal fluid (CSF) of most patients with narcolepsy, we hypothesized the presence of a deficient hypocretinergic transmission in DLB. Hypocretin-1 was tested in the CSF of 10 DLB patients. Levels were found to be in the normal range (mean 521 pg/ml, range 382-667) when compared to controls (n = 20, mean 497 pg/ml, range 350-603) and Alzheimer's disease patients (n = 7, mean 474 pg/ml, range 333-564). In DLB, excessive daytime sleepiness, hallucinations and REM sleep behavior may occur in the absence of a detectable hypocretin deficiency. 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15256827     DOI: 10.1159/000079749

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  12 in total

1.  Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population.

Authors:  Stine Knudsen; Poul J Jennum; Jørgen Alving; Søren Paludan Sheikh; Steen Gammeltoft
Journal:  Sleep       Date:  2010-02       Impact factor: 5.849

2.  Parkinsonism with excessive daytime sleepiness--a narcolepsy-like disorder?

Authors:  Christian Baumann; Luigi Ferini-Strambi; Daniel Waldvogel; Esther Werth; Claudio Lino Bassetti
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

3.  Hypocretin-1 (orexin A) levels are normal in Huntington's disease.

Authors:  Christian R Baumann; Martin Hersberger; Claudio L Bassetti
Journal:  J Neurol       Date:  2006-04-05       Impact factor: 4.849

4.  Sleep Disorders in Atypical Parkinsonism.

Authors:  Sabra M Abbott; Aleksandar Videnovic
Journal:  Mov Disord Clin Pract       Date:  2014-06-01

5.  Hypocretin measurement: shelf age of radioimmunoassay kit, but not freezer time, influences assay variability.

Authors:  Glenda Keating; Donald L Bliwise; Prabhjyot Saini; David B Rye; Lynn Marie Trotti
Journal:  Scand J Clin Lab Invest       Date:  2017-05-24       Impact factor: 1.713

6.  CSF prostaglandin D synthase is reduced in excessive daytime sleepiness.

Authors:  Claudio L Bassetti; Martin Hersberger; Christian R Baumann
Journal:  J Neurol       Date:  2006-04-05       Impact factor: 4.849

7.  Evidence for metabolic hypothalamo-amygdala dysfunction in narcolepsy.

Authors:  Rositsa Poryazova; Betina Schnepf; Esther Werth; Ramin Khatami; Ulrike Dydak; Dieter Meier; Peter Boesiger; Claudio L Bassetti
Journal:  Sleep       Date:  2009-05       Impact factor: 5.849

Review 8.  Focus on the Complex Interconnection between Cancer, Narcolepsy and Other Neurodegenerative Diseases: A Possible Case of Orexin-Dependent Inverse Comorbidity.

Authors:  Maria P Mogavero; Alessandro Silvani; Lourdes M DelRosso; Michele Salemi; Raffaele Ferri
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

9.  Cerebrospinal fluid orexin in Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Spencer P Treu; David T Plante
Journal:  Sleep Med       Date:  2021-07-13       Impact factor: 4.842

10.  Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy.

Authors:  Yves A Dauvilliers; Sylvain Lehmann; Isabelle Jaussent; Audrey Gabelle
Journal:  Front Aging Neurosci       Date:  2014-06-11       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.